New treatment option for Major Depressive Diorder
Official title qEEG Brain Signature of Depression & Neuromodulation-induced Recovery
ClinicalTrials.gov ID: NCT06719427
What this study is testing
- What it's testing
- This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- A diagnosis of Depression based on Diagnostic and Statistical Manual (DSM) 5.0 criteria.
- Receiving a neuromodulation (rTMS) treatment for depression at the HCN
- Physically healthy
- Age 18-80, inclusive.
- Able to provide informed consent and comply with the study protocol.
You likely can't join if
- that is the cause of the communication difficulties. Exclusion Criteria:
- Moderate substance use disorder or greater severity based on DSM 5.0 criteria and confirmed by a study MD on clinical assessment.
- Mild and major comorbid medical conditions (as determined by investigators - e.g., neurological diseases, uncontrolled hypertension or diabetes...
- A major comorbid psychiatric disorder (as determined by investigators - e.g., schizophrenia or bipolar disorder) and/or psychosis at the time of...
- History of seizure disorder
- Pregnant
See the full eligibility criteria
- A diagnosis of Depression based on Diagnostic and Statistical Manual (DSM) 5.0 criteria.
- Receiving a neuromodulation (rTMS) treatment for depression at the HCN
- Physically healthy
- Age 18-80, inclusive.
- Able to provide informed consent and comply with the study protocol.
- Patients will not be excluded solely based on communication (i.e., non-English speaking) unless they have
- that is the cause of the communication difficulties. Exclusion Criteria:
- Moderate substance use disorder or greater severity based on DSM 5.0 criteria and confirmed by a study MD on clinical assessment.
- Mild and major comorbid medical conditions (as determined by investigators - e.g., neurological diseases, uncontrolled hypertension or diabetes, malignancy)
- A major comorbid psychiatric disorder (as determined by investigators - e.g., schizophrenia or bipolar disorder) and/or psychosis at the time of study enrollment.
- History of seizure disorder
- Pregnant
The study team makes the final eligibility decision.
Where it's taking place
- North York, Ontario, Canada
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include North York, Ontario, Canada; Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.